601607 Shanghai Pharmaceuticals Holding
- 18.77
- -0.15-0.79%
Shanghai Pharmaceuticals Holding News
Announcement from sh pharma on the approval of production of ibuprofen tablets.
Announcement of Approval of Production of Sitagliptin Phosphate Tablets by Shanghai Pharmaceuticals Group Co., Ltd.
Announcement from sh pharma regarding the clinical trial approval notice for WST03 preparation.
Legal Opinion of Guohao Law Firm (Shanghai) on the Shanghai Pharma Group Co., Ltd.'s 2023 Annual Shareholders' Meeting.
Announcement of the 2023 Annual Shareholders' Meeting Resolutions of SH Pharma Group Co., Ltd.
Announcement of sh pharma's approval of the listing application for hydrocortisone active pharmaceutical ingredient.
Announcement: Approval of the market application of the active pharmaceutical ingredient sodium warfarin by SH Pharma Group Co., Ltd.
Notice on Convening the 2023 Annual Shareholders' Meeting of sh pharma Group Co., Ltd.
Announcement on the Progress of Pharmaceutical Clinical Trials by SH Pharma Group Co., Ltd.
Notice of Shanghai Pharma Holding Co., Ltd. on Convening the Annual Shareholders' Meeting in 2023.
Meeting documents for the 2023 Annual Shareholders' Meeting of Sh Pharma Group Co., Ltd.
Announcement of Shanghai Pharma Group Co., Ltd. regarding the mid-term dividend arrangement for 2024.
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on approval for production of maxitengtan tablets
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on the resignation of a director
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on I040 receiving a clinical trial approval notice
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on approval of the marketing application for perindopril tert-butylamine
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on approval for production of sacubatl valsartan tablets
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on approval for production of injectable methotrexate
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on I031 receiving a clinical trial approval notice
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on approval for production of levosimendan injection
Analysis
Price Target
No Data
